Results 201 to 210 of about 248,151 (219)

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

Journal of the American College of Cardiology, 2021
Martin Bødtker Mortensen, Anne Langsted, BØRge G Nordestgaard   +2 more
exaly  

Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study

European Heart Journal, 2021
Renato Quispe, Erin D Michos, Isha Lamba   +2 more
exaly  

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

Lancet, The, 2010
A Keech, J Simes
exaly  

LDL-cholesterol concentrations: a genome-wide association study

Lancet, The, 2008
Manjinder S Sandhu, Dawn M Waterworth, Kijoung Song   +2 more
exaly  

The LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk

Journal of the American College of Nutrition, 2008
Maria Luz Fernández
exaly  

Regulation of Plasma LDL-Cholesterol Levels by Dietary Cholesterol and Fatty Acids

Annual Review of Nutrition, 1993
D K Spady, Laura A Woollett, John M Dietschy   +2 more
exaly  

Cholesterol Absorption and Metabolism and LDL Kinetics in Healthy Men With Different Apoprotein E Phenotypes and Apoprotein BXbaI and LDL ReceptorPvuII Genotypes

Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
Helena Gylling, Kimmo Kontula, T A Miettinen   +2 more
exaly  

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

Lancet, The, 2009
John Jp Kastelein, Wolfgang Koenig, Peter Libby   +2 more
exaly  

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Lancet, The, 2017
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park   +2 more
exaly  

Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment

Pathology, 2019
Amanda J Hooper, David R Sullivan, John R Burnett   +2 more
exaly